Comparing the current results to its competitors, Supernus Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2026 by 38.63 % year on year. The sales growth was above Supernus Pharmaceuticals Inc 's competitors' average revenue growth of 8.63 %, achieved in the same quarter.
Supernus Pharmaceuticals inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 55.47 %
Strong sales growth of 38.63 % in Overall company contributed to Supernus Pharmaceuticals inc increase in total revenue by 38.63 % Supernus Pharmaceuticals inc improved its market share in this segment, to approximately 0.37 %.
April 8, 2024
Supernus Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in Rockville, Maryland, specializing in the development and commercialization of products for the treatment of central nervous system (CNS) diseases, announced new progress regarding the ongoing regulatory procedures of the SPN-830 infusion device. SPN-830, an investigational apomorphine infusion device, is under scrutiny by the U.S. Food and Drug Administration (FDA) as a promising method for the continuous administration of medication to manage motor fluctuations in patients battling Parkinson s Disease (PD).Parkinson s, a chronic and progressive neurodegenerative disorder affecting the movement, often causes motor fluctuations known as...
Publicly Traded Peers of Supernus Pharmaceuticals inc
Collegium Pharmaceutical Inc Share Performance
-48.69%
This Year
Collegium Pharmaceutical Inc
Profile
Collegium Pharmaceutical Inc's business model revolves around the development and commercialization of innovative products specifically designed to address the limitations of existing treatment options in pain management. They focus on developing extended-release formulations that offer abuse-deterrent properties to enhance patient safety and combat prescription drug abuse. By leveraging strategic partnerships, they aim to bring their products to market efficiently and effectively.
United Therapeutics Corporation's business model revolves around the development and commercialization of innovative therapeutics for treating rare diseases and chronic conditions. They focus on researching, manufacturing, marketing, and distributing their specialized pharmaceutical and medical products to healthcare providers and patients globally.
Ligand Pharmaceuticals Inc operates on a business model focused on discovering and acquiring new drugs and technologies to license them to pharmaceutical companies. They generate revenue through licensing fees, milestone payments, and royalties from the sales of their partnered products. Their approach allows them to leverage their expertise and resources while minimizing risk, ultimately leading to long-term value creation for their shareholders.
Durect Corp operates as a specialty pharmaceutical company that develops and commercializes innovative products for the treatment of chronic diseases. Their business model revolves around the research, development, and commercialization of their proprietary drug delivery technologies and therapeutics to address unmet medical needs.
Sources:
Supernus Pharmaceuticals inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Supernus Pharmaceuticals inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
